Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States-Reference-Cited by-同舟云学术

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States

Published:2023-09 Issue: Volume:25 Page:100566
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Adegunsoye Ayodeji^ORCID,Baccile Rachel^ORCID,Best Thomas J.^ORCID,Zaksas Victoria^ORCID,Zhang Hui,Karnik Rasika,Patel Bhakti K.,Solomonides Anthony E.^ORCID,Parker William F.,Solway Julian

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Internal Medicine,Health Policy

Reference60 articles.

1. COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial;Sahanic;ERJ Open Res,2023

2. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study;Huang;Lancet Respir Med,2022

3. Longitudinal assessment of chest CT findings and pulmonary function after COVID-19 infection;Han;Radiology,2023

4. COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts;John;Immunol Rev,2021

5. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study;Shi;Lancet Infect Dis,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiological and spirometric changes in relation to drugs used in post COVID pulmonary fibrosis in a cohort of COVID-19 survivors;The Egyptian Journal of Bronchology;2024-09-04

2. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows;Pharmaceuticals;2024-05-30

3. Persistent lung inflammation and alveolar-bronchiolization due to Notch signaling dysregulation in SARS-CoV-2 infected hamster;2024-05-13

4. Beyond the Acute Phase: Long-Term Impact of COVID-19 on Functional Capacity and Prothrombotic Risk—A Pilot Study;Medicina;2023-12-27

5. Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection–response to Guangting Zeng and Yuchi Zhou;The Lancet Regional Health - Americas;2023-10